Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen
Completed · Phase 2/Phase 3
Conditions studied: HIV-1
In brief
The primary objective of this study is to confirm the TAF dose and to evaluate the pharmacokinetics (PK) of TAF, safety, and tolerability of F/TAF in children and adolescents with HIV-1 who are virologically suppressed (defined as having \< 50 copies/mL of HIV-1 ribonucleic acid (RNA) for a period of at least 6 months) while on a stable 2 NRTI containing regimen.
Key facts
- Study ID
- NCT02285114
- Run by
- Gilead Sciences
- People needed
- 41
- Starts
- 2015-01-20
- Expected to finish
- 2024-12-11
- Last updated by the study team
- 2025-06-27
Who can join
Age: 0 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California Los Angeles — Los Angeles, California, United States
- Children's Hospital Colorado — Aurora, Colorado, United States
- St. Christopher's Hospital for Children — Philadelphia, Pennsylvania, United States
- Seattle Children's Hospital — Seattle, Washington, United States
- Hospital del Nino — Panama City, Panama
- Rahima Moosa Mother and Child Hospital — Johannesburg, Coronationville, South Africa
- KIDCRU, Ward J8, Tygerberg Children's Hospital — Cape Town, South Africa
- Be Part Yoluntu Centre — Cape Town, South Africa
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.